Skip to main content
Top
Published in: Pituitary 1/2016

01-02-2016

Surgical management of pituitary metastases

Authors: T. Burkhardt, M. Henze, L. A. Kluth, M. Westphal, N. O. Schmidt, J. Flitsch

Published in: Pituitary | Issue 1/2016

Login to get access

Abstract

Background

Pituitary metastases are rare and commonly described in case reports or small case series. Due to its rarity this entity is not subject to standardized treatment guidelines, there is debate about typical initial symptoms that may lead to finding the correct diagnosis and information about the clinical course is also sparse.

Methods

We have conducted a retrospective analysis of patients with pituitary metastases who were surgically treated via a transsphenoidal procedure at our institution between 2006 and 2014. Underlying primary disease, clinical and surgical course as well as adjuvant radiotherapy and follow-up data are presented.

Results

14 patients met the inclusion criteria (8 female, 6 male). Mean age was 61.5 years. Most patients became symptomatic with visual symptoms—both visual deterioration and/or diplopia (n = 13)—and anterior lobe insufficiency (n = 8). Surprisingly diabetes insipidus was only seen in three patients. All patients underwent transsphenoidal surgery initially, four patients had to undergo surgery for residual tumor or recurrence, two of them via a transcranial route. Breast cancer was the most common entity (n = 6), followed by prostate cancer (n = 3), nsclc (n = 2) and melanoma, thyroid cancer and renal cancer in one case each. Postoperative MRI showed gross total resection in four cases and residual disease in eight cases (subtotal resection, partial resection and biopsy), two patients files were incomplete regarding MRI-results. All patients underwent adjuvant radiotherapy. Survival after the initial diagnosis of cancer was 36 and 16 months after diagnosis of pituitary metastases.

Conclusion

Our results indicate that transsphenoidal surgery is a safe method to resect pituitary metastases and that the extend of resection does not have an influence on survival time. Our results also indicate that diabetes insipidus may not be the most common initial symptom of pituitary metastases and lack thereof should not lead to making a wrong diagnosis and delaying appropriate therapy.
Literature
1.
go back to reference Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. doi:10.1530/eje.1.02326 PubMedCrossRef Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. doi:10.​1530/​eje.​1.​02326 PubMedCrossRef
2.
go back to reference Quaresma M, Coleman MP, Rachet B (2014) 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. doi:10.1016/S0140-6736(14)61396-9 PubMed Quaresma M, Coleman MP, Rachet B (2014) 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. doi:10.​1016/​S0140-6736(14)61396-9 PubMed
3.
go back to reference He W, Chen F, Dalm B, Kirby PA, Greenlee JD (2014) Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary. doi:10.1007/s11102-014-0552-2 PubMed He W, Chen F, Dalm B, Kirby PA, Greenlee JD (2014) Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary. doi:10.​1007/​s11102-014-0552-2 PubMed
4.
go back to reference Fassett DR, Couldwell WT (2004) Metastases to the pituitary gland. Neurosurg Focus 16(4):E8PubMed Fassett DR, Couldwell WT (2004) Metastases to the pituitary gland. Neurosurg Focus 16(4):E8PubMed
9.
go back to reference McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79PubMedCrossRef McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79PubMedCrossRef
11.
go back to reference Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1):74–85PubMedCrossRef Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1):74–85PubMedCrossRef
12.
go back to reference Marin F, Kovacs KT, Scheithauer BW, Young WF Jr (1992) The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical study of 125 cases. Mayo Clin Proc 67(10):949–956PubMedCrossRef Marin F, Kovacs KT, Scheithauer BW, Young WF Jr (1992) The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical study of 125 cases. Mayo Clin Proc 67(10):949–956PubMedCrossRef
13.
go back to reference Houck WA, Olson KB, Horton J (1970) Clinical features of tumor metastasis to the pituitary. Cancer 26(3):656–659PubMedCrossRef Houck WA, Olson KB, Horton J (1970) Clinical features of tumor metastasis to the pituitary. Cancer 26(3):656–659PubMedCrossRef
14.
go back to reference Kimmel DW, O’Neill BP (1983) Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 52(12):2355–2358PubMedCrossRef Kimmel DW, O’Neill BP (1983) Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 52(12):2355–2358PubMedCrossRef
15.
go back to reference Oi S, Ciric I, Mayer TK (1978) Metastatic breast carcinoma in the pituitary gland. Brain Nerve 30(1):69–73PubMed Oi S, Ciric I, Mayer TK (1978) Metastatic breast carcinoma in the pituitary gland. Brain Nerve 30(1):69–73PubMed
16.
go back to reference Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, Thalassinos NC (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89(2):574–580. doi:10.1210/jc.2003-030395 PubMedCrossRef Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, Thalassinos NC (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89(2):574–580. doi:10.​1210/​jc.​2003-030395 PubMedCrossRef
17.
18.
go back to reference Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305(10):545–551. doi:10.1056/NEJM198109033051003 PubMedCrossRef Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305(10):545–551. doi:10.​1056/​NEJM198109033051​003 PubMedCrossRef
19.
go back to reference Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24(12):1868–1876. doi:10.1200/JCO.2005.04.7423 PubMedCrossRef Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24(12):1868–1876. doi:10.​1200/​JCO.​2005.​04.​7423 PubMedCrossRef
20.
go back to reference Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L, Group, E.R.O., Genito-Urinary Tract Cancer, G. (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi:10.1056/NEJMoa0810095 PubMedCrossRef Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L, Group, E.R.O., Genito-Urinary Tract Cancer, G. (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi:10.​1056/​NEJMoa0810095 PubMedCrossRef
21.
go back to reference Early Breast Cancer Trialists’ Collaborative, G., Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8 CrossRef Early Breast Cancer Trialists’ Collaborative, G., Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.​1016/​S0140-6736(11)60993-8 CrossRef
23.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. doi:10.1016/j.eururo.2013.11.002 PubMedCrossRef Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. doi:10.​1016/​j.​eururo.​2013.​11.​002 PubMedCrossRef
24.
go back to reference Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32(3):669–676. doi:10.1007/s00345-013-1157-5 PubMedCrossRef Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32(3):669–676. doi:10.​1007/​s00345-013-1157-5 PubMedCrossRef
25.
go back to reference Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132(7):566–577PubMedCrossRef Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132(7):566–577PubMedCrossRef
26.
27.
go back to reference Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. doi:10.1056/NEJMoa1405095 PubMedPubMedCentralCrossRef Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. doi:10.​1056/​NEJMoa1405095 PubMedPubMedCentralCrossRef
Metadata
Title
Surgical management of pituitary metastases
Authors
T. Burkhardt
M. Henze
L. A. Kluth
M. Westphal
N. O. Schmidt
J. Flitsch
Publication date
01-02-2016
Publisher
Springer US
Published in
Pituitary / Issue 1/2016
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-015-0676-z

Other articles of this Issue 1/2016

Pituitary 1/2016 Go to the issue